Crossmark

Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: results of a single center study

Crossref DOI link: https://doi.org/10.1007/s00277-025-06389-9

Published Online: 2025-05-20

Published Print: 2025-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Ting

Wang, Li

Jiang, Hui

Huang, Shujuan

Xu, Haitao

Wang, Anyou

Liu, Xin
License Information

Text and Data Mining valid from 2025-05-01

Version of Record valid from 2025-05-20
More Information

Article History

Received: 12 December 2024

Accepted: 26 April 2025

First Online: 20 May 2025

Declarations

:

: This study was approved, and the written informed consent was waived by the ethics committee of the first affiliated hospital of University of Science and Technology of China (2024-RE-449) due to the retrospective nature of the review, and confirmed that the data was anonymized and maintained with confidentiality. The study was conducted in accordance with the Declaration of Helsinki.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below